Synthesis and *In Vitro* Antiproliferative Evaluation of Some B-norcholesteryl thiazole Derivatives

Yanmin Huang¹, Binbin Qi¹, Jianguo Cui²*, Zhipin Liu¹, Chunfang Gan³, Dandan Zhao¹, Qifu Lin² and Haixin Shi²*

¹College of Chemistry and Material Science, Guangxi Teachers Education University, Nanning, China
²Guangxi Colleges and University Key Laboratory of Beibu Gulf Oil and Natural Gas Resource Effective Utilization, Qizhou University, China

**Abstract**

Some novel B-norcholesteryl thiazole derivatives were synthesized and their structures were characterized by IR, NMR and HRMS. The antiproliferative activity of the compounds against human cervical carcinoma (HeLa), human lung carcinoma (A549), human liver carcinoma (HEPG2) and normal kidney epithelial (HEK293T) cells was assayed. The results revealed that compounds 14 and 17 with a structure of N-methylthiazole showed distinct antiproliferative activity against A549 and HEPG2 cells. Compounds 20-24 with a structure of N-phenylthiazole displayed a selective antiproliferative activity on HeLa cells and were almost inactive to normal kidney epithelial cells (HEK293T). The research provided a theoretical reference for the exploration of new anti-cancer agents and may be useful for the design of novel chemotherapeutic drugs.

**Keywords:** Cholesterol; B-norcholesteryl thiazoles; B-norcholesteryl N-methylthiazoles; B-norcholesteryl N-phenylthiazoles; Antiproliferative activity

**Introduction**

Steroidal compounds show various biological activity and play a very important role in life. The steroidal drugs have been used widely in traditional medicines, such as anti-inflammatory, antimicrobial, anticarcinogen, hypotensive, hormone kind medication, hypcholesterolemic and diuretic activities, etc. [1-8].

Recently, a variety of steroid compounds with unusual and interesting structures have been isolated from marine life or plants, and synthesized [9-12]. Among these steroid compounds, sterols with the structure of B-nor-steroidal nucleus are rarely reported and are uncommon in nature. Wentworth et al. reported that 3β, 5β-dihydroxy- B-norcholesteryl-6β-formaldehyde with a structure of [6,5,6,5]-fused ring might be generated by ozonolysis of cholesterol in *vivo* because of the cause of some human disease [13]. Moreover, several sterols possessing a skeleton of [6,5,6,5] fused ring were isolated by Wang et al. [14], Miyamoto et al. [15] and Xiaomei et al. [16] and synthesized by Xiaomei et al. [17].

In order to investigate the anti-tumor activity of new steroidal derivatives, we synthesized a series of steroidal derivatives possessing [6,5,6,5]-fused ring, various side chains and substituted groups on the steroidal nucleus, and determined their antiproliferative activities against different types of cancer cells [18-20]. The results showed that presence of a cholesterol-type side chain was very important in determining the cytotoxicity of these compounds, and presence of a thiosemicarbazone group on the C-6 position of steroidal nucleus could enhance the antiproliferative activity of the compound.

Hetero steroids have been obtained a great amount of attention over the years by medicinal chemists for drug discovery. Introducing a heterocycle or a heteroatom into steroids will greatly affect the chemical property of a steroid and often result in useful alterations in its biological activity [21,22]. So far, the steroids containing heterocycles or heteroatoms have been widely explored and reported [23]. Literatures suggested that such compounds displayed distinct cytotoxicity against cancer cell lines [24-28].

Recently, we synthesized some novel B-norcholesteryl benzimidazole and benzothiazole derivatives with [6,5,6,5]-fused ring and assayed their antiproliferative activity against some cancer cells [29]. The results showed that some B-norcholesteryl benzimidazole compounds exhibited an excellent antiproliferative activity and almost inactive to normal kidney epithelial cells (HEK293T). Thiazole ring is a pharmacophore with extensive bioactivities, such as antimicrobial, anti-inflammatory, anticancer, anti-HIV-1, anticonvulsant etc. [30-33]. In order to obtain biologically potent anticancer compounds with diverse structures, as an extension of our previous work, a series of B-norsteroidal derivatives possessing a [6,5,6,5]-fused ring and a structure of 6-thiazole had been prepared starting from cholesterol in the present study. Meanwhile the antiproliferative activity of compounds *in vitro* was evaluated further.

**Results and Discussion**

**Chemistry**

Scheme 1 outlines a synthetic procedure of B-norcholesteryl thiazole derivatives (5-10). Compound 4 was prepared according to Gan et al. [18]. The configurations of C-5 and C-7 in compound 3 had been described in references [13,34,35]. Compound 4 were obtained by the reaction of 3 with thiosemicarbazide. The reaction of compound 4 with α-bromoacetophenone afforded a corresponding B-norcholesteryl thiazole derivative.

*Corresponding authors: Jianguo Cui, Haixin Shi, Guangxi Colleges and University Key Laboratory of Beibu Gulf Oil and Natural Gas Resource Effective Utilization, Qizhou University, China, E-mail: cuitj954@sina.com; shihaixin20061@163.com

Received July 21, 2015; Accepted August 15, 2015; Published August 20, 2015

Citation: Huang Y, Qi B, Cui J, Liu Z, Gan C, et al. (2015) Synthesis and *In Vitro* Antiproliferative Evaluation of Some B-norcholesteryl thiazole Derivatives. Med Chem 5: 405-411. doi: 10.4172/2161-0444.1000292

Copyright: © 2015 Huang Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
thiazole derivative 5. The 1H NMR and 13C NMR spectra of 5 were the basis of its structure elucidation. In the NMR spectrum, resonances signals of Ph-Н at δ 7.75, 7.38, 7.30 ppm and Ph-C at δ 128.7-102.8 ppm demonstrated the presence of a benzene ring in compound 5. The 1H NMR spectrum showed a singlet at δ 7.14 indicating a thiazole proton. Moreover, the 13C NMR spectrum showed three signals at δ 169.9, 147.7, 134.8 ppm indicating the formation of thiazole ring in 5 further. The HREI mass spectra of compound 5 exhibited molecular ion peak at m/z 592.3923. All spectrums confirmed the structure of compound 5.

To survey the effect of various substituent groups in benzene ring on the antiproliferative activity of compounds, compounds (6-10) were synthesized by the reaction of 4 with different 4-substituted-ω-bromoacetophenones. Their structures had been confirmed on analytical and spectral data.

In order to investigate the effect of substituted groups on thiazole ring against the antiproliferative activity, we prepared a series of B-norcholesterol N-methyl- and N-phenylthiazole derivatives (12-24) by reacting compound 11 or 18 with various ω-bromoacetophenones (Scheme 2 and 3). The structures of all synthesized compounds had been confirmed by analysis of IR, NMR and HRMS.

Biological results and discussion

Lung cancer and liver cancer are a main cause of death in cancer patients. To investigate the antiproliferative activity of the new compounds, we determined their IC50 values on A549 (human lung carcinoma), HEPG2 (human liver carcinoma) and HeLa (human cervical carcinoma) using a MTT assay, and non-cancer cells HEK293T (Normal Kidney Epithelial Cells) were showed as IC50 values (concentration of a compound allowing survival of 50% of the cells in a population) in µM in Table 1.

As shown in Table 1, these B-norcholesteryl thiazole derivatives (5-19) didn’t exhibited obvious antiproliferative activity against tested cancer cells except compound 14 which showed distinct cytotoxicity on all tested cancer cells and 17 possessed of a moderate cytotoxicity on A549 and HEPG2 cells. Compared with the result of our previous work [20,29], we think that a main cause of the less activity of these compounds may be a greater size of 5-phenyl group on thiazole ring resulted to the interaction of comopounds with the cells can’t take place, which deserves further study.

However, it was interesting that compounds 20-24 with a N-phenylthiazole ring displayed distinct antiproliferative activity against HeLa cells and were almost inactive to other cancer cells and normal kidney epithelial cells. The results exhibited that compounds 20-24 were better selective inhibitors against HeLa cells, and are worth to study further.

Experimental Section

Chemistry

The sterols were purchased from Sinopharm Chemical Reagent Co., Ltd, Shanghai, China. All chemicals and solvents were analytical grade. Melting points were determined on an X apparatus (Beijing Tech Instrument Co. Ltd., Beijing, China) and were uncorrected. The 1H and 13C NMR spectra were recorded in CDCl3 on a Bruker AV-600 spectrometer at working frequencies 600 and 150 MHz, and a Bruker AV-300 spectrometer at working frequencies 300 and 75 MHz respectively. Chemical shifts are expressed in parts per million (δ) values and coupling constants (J) in Hertz. Infrared spectra were measured with a Thermo Scientific Nicolet IS-10 Spectrophotometer (Thermo Scientific, America). HREIMS was measured on an Agilent 6210 TOFMS instrument (Agilent Technologies, America). The cell proliferation assay was undertaken by a MTT method using 96-well plates on a MLLTISKAN MK3 analysis spectrometer (Thermo Scientific, Shanghai, China).

The compound 4 was prepared according to the method of Gan et al. [18].

General procedure for the synthesis of compounds 5-10: ω-Bromoacetophenone or its 4-substituted derivative (0.45 mmol) was added to a solution of compound 4 (0.3 mmol) in CH3OH (50 mL). The solution was stirred for 2-3 h at 60°C until no starting material was observed (the progress of the reaction was monitored by TLC, petroleum ether/ethyl acetate=1:1). Then the reaction was stopped and the majorit of solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (300-400 mesh) to afford the corresponding target products 5-10.

α) 1-(3β,5β-Dihydroxy-6’-B-norcholestereryl-6E-ylidene)-2-(5’-phenyl-2’-thiazol)hydrazone (5): Yellow oil, yield: 71%. IR (KBr) ν/cm-1: 3439, 2953, 2858, 1706, 1567, 1442, 1380, 1325, 1071, 1051, 1024; 1H NMR (300 MHz, CDCl3): δ: 7.75 (1H, d, J=7.2, 2.6-PhH ), 7.38 (2H, t, J=7.8, 3.5-PhH), 7.30 (1H, m, 4-PhH), 7.14 (1H, d, J=6.4, C6-H), 6.73 (1H, s, 4-ArH), 4.17 (1H, br s, -OH), 3.46 (1H, s, -OH), 2.18-2.12 (2H, m, C7-H and C8-H), 0.94 (3H, d, J=6.3, 21-CH3), 0.80 (3H, s, 19-CH3), 0.88 (6H, d, J=6.0, 26- and 27-CH3), 0.72 (3H, s, 18-CH3); 13C
Citation: Huang Y, Qi B, Cui J, Liu Z, Gan C, et al. (2015) Synthesis and In Vitro Antiproliferative Evaluation of Some B-norcholesteryl thiazole Derivatives. Med chem 5: 405-411. doi: 10.4172/2161-0444.1000292

NMR (75 MHz, CDCl₃) δ: 169.9 (2-ArC), 150.7 (6-C), 147.7 (4-ArC), 134.8 (5-ArC), 128.6 (1'-PhC), 127.7 (2',6'-PhC), 126.0 (4'-PhC), 128.6 (3',5'-PhC), 83.7 (5-C), 67.0 (3-C), 56.4 (17-C), 56.05 (14-C), 55.7 (7-C), 52.0 (9-C), 45.4 (4-C), 44.7 (8-C), 43.5 (10-C), 42.5 (12-C), 39.8 (24-C), 39.5 (4-C), 36.3 (22-C), 35.6 (20-C), 28.7 (1-C), 28.6 (2-C), 28.0 (16-C), 27.7 (25-C), 24.7 (15-C), 23.9 (23-C), 22.8 (26-C), 22.6 (27-C), 21.6 (11-C), 18.8 (21-C), 18.2 (19-C), 12.6 (18-C); HREIMS m/z: 592.3923 [M+H]+ (calcd. for C₃₆H₅₄N₃O₂S, 592.3937).

1-(3β,5β-Dihydroxy-6'-B-norcholesteryl-6E-ylidene)-2-[5'-(p-trifluoromethylphenyl)-2'-thiazol]hydrazone (6): Yellow oil, yield: 73%, IR (KBr) ν/cm⁻¹: 3416, 2945, 2863, 1709, 1614, 1564, 1524, 1448, 1409, 1377, 1320, 1170, 1125, 1066, 1013; ¹H NMR (300 MHz, CDCl₃) δ: 8.11 (1H, d, J=8.1 Hz, Ar-H), 7.83 (2H, d, J=8.1, 2,6-PhH), 7.78 (1H, d, J=8.1, C6-H), 7.62 (2H, d, J=8.1, 3,5-PhH), 7.26 (1H, s, -NH), 6.82 (1H, s, 4-ArH), 4.46 (1H, s, -OH), 4.19 (1H, br s, C3-H), 4.13 (1H, dd, J=14.1, 6.9, C7-H), 3.45 (1H, s, -OH), 2.22-2.16 (2H, m, C4-H), 0.93 (3H, d, J=6.6, 21-CH₃), 0.92 (3H, s, 19-CH₃), 0.87 (6H, d, J=6.6, 26- and 27-CH₃), 0.72 (3H, s, 18-CH₃); ¹³C NMR (75 MHz, CDCl₃) δ: 170.0 (2-ArC), 148.8 (6-C), 137.6 (5-ArC), 129.7 (1-PhC), 129.3 (4-ArC), 126.1 (2'-6'-PhC), 125.9 (3',5'-PhC), 125.6 (4'-PhC), 104.8 (CF₃), 83.7 (5-C), 67.1 (3-C), 56.4 (17-C), 56.1 (14-C), 55.6 (7-C), 52.0 (9-C), 45.4 (4-C), 44.7 (8-C), 43.5 (10-C), 42.5 (12-C), 39.8 (24-C), 39.5 (4-C), 36.3 (22-C), 35.6 (20-C), 28.7 (1-C), 28.6 (2-C), 28.0 (16-C), 27.7 (25-C), 24.7 (15-C), 23.9 (23-C), 22.8 (26-C), 22.6 (27-C), 21.6 (11-C), 18.8 (21-C), 18.2 (19-C), 12.6 (18-C); HREIMS m/z: 592.3923 [M+H]+ (calcd. for C₃₆H₅₄N₃O₂S, 592.3937).

Table 1: In vitro antiproliferative activities (IC₅₀ in μM) of compounds 5-24.

| Compounds | Cells | Cells | Cells | Cells |
|-----------|-------|-------|-------|-------|
|           | HeLa  | A549  | HEPG2 | HEK293T |
| 5         | >80   | >80   | >80   | >80     |
| 6         | >80   | >80   | >80   | >80     |
| 7         | >80   | >80   | >80   | >80     |
| 8         | >80   | >80   | >80   | >80     |
| 9         | >80   | >80   | >80   | >80     |
| 10        | >80   | >80   | >80   | >80     |
| 12        | >80   | >80   | >80   | >80     |
| 13        | >80   | >80   | >80   | >80     |
| 14        | >80   | >80   | 30.2  | >80     |
| 15        | >80   | >80   | >80   | >80     |
| 16        | >80   | >80   | >80   | >80     |
| 17        | >80   | 32.5  | 19.8  | >80     |
| 19        | >80   | >80   | >80   | >80     |
| 20        | >80   | >80   | >80   | >80     |
| 21        | >80   | >80   | >80   | >80     |
| 22        | >80   | >80   | >80   | >80     |
| 23        | >80   | >80   | >80   | >80     |
| 24        | >80   | >80   | >80   | >80     |
| Cisplatin | >80   | >80   | >80   | >80     |
|           | 50.9  | >80   | >80   | >80     |
|           | 24.8  | >80   | >80   | >80     |
|           | 17.6  | >80   | >80   | >80     |
|           | 38.7  | >80   | >80   | >80     |
|           | 21.7  | >80   | >80   | >80     |
|           | 24.7  | >80   | >80   | >80     |
|           | 10.1  | 2.3   | 67    | 10.3    |
37.6 (22-C), 37.0 (20-C), 30.0 (1-C), 29.7 (2-C), 29.4 (16-C), 28.6 (12-C), 28.2 (27-C), 26.2 (22-C), 23.7 (15-C), 23.9 (23-C), 22.8 (26-C), 22.6 (25-C), 21.1 (16-C), 18.8 (21-C), 18.2 (19-C), 12.6 (18-C); HREIMS m/z: 671.3898 [M+H]+ (calcd. for C_{38}H_{33}N_5O_7S, 671.3898).

Compounds 12-17 were prepared similarly according to the procedure of 5-10, but using compound 11 as a reactive substrate. Compounds 11 was prepared according to Gan et al. [20].

a1) 1-(3β,5β-Dihydroxy-6'-B-norcholesteryl-6-E-ylidene)-2-(N-methyl-5'-phenylazo(thiazol-2(3H))ylidene)azine (12): Brownish oil; yield: 76%. IR (KBr) ν/cm⁻¹: 3492, 2926, 1625, 1556, 1451, 1368, 1019, 1123; 1H NMR (300 MHz, CDCl₃) δ: 7.77 (1H, d, J=5.4, C6-H), 7.45-7.3 (3H, m, 3',4',5'-PhH), 7.36-7.34 (2H, m, 2',6'-PhH), 5.92 (1H, s, C3-H), 4.74 (1H, t, J=5.4, C1-H), 4.01 (1H, br, s, -OH), 3.71 (1H, br, s, -OH), 3.29 (3H, s, C3-H), 2.78 (1H, dd, J=9.0, 5.1, C7-H), 2.11-2.04 (2H, m, C8-H and C4-H); 0.98 (3H, s, C19-CH₃), 0.93 (3H, d, J=6.6, 21-CH₃), 0.87 (3H, d, J=6.6, 26- and 27-CH₃), 0.69 (3H, s, C18-CH₃); 13C NMR (75 MHz, CDCl₃) δ: 169.8 (2-ArC), 157.7 (6-C), 140.9 (1'-PhC), 131.0 (1'-PhC), 129.2 (4'-PhC), 128.8 (2'-PhC), 128.7 (3'-PhC), 98.8 (4'-ArC). 83.2 (5-C), 67.2 (3-C), 56.6 (15-C), 55.7 (14-C), 54.3 (7-C), 50.0 (9-C), 45.2 (13-C), 44.9 (10-C), 44.8 (12-C), 44.6 (24-C), 39.9 (N-CH₃), 39.5 (4-C), 36.2 (8-C), 35.7 (22-C), 28.0 (13-C), 27.3 (25-C), 24.9 (15-C), 23.8 (28-C), 22.6 (25-C), 22.5 (27-C), 21.6 (11-C), 18.8 (21-C), 18.9 (19-C), 12.6 (18-C); HREIMS m/z: 606.4104 [M+H]+ (calcd. for C_{38}H_{33}N_5O_7S, 606.4093).

b1) 1-(3β,5β-Dihydroxy-6'-B-norcholesteryl-6-E-ylidene)-2-[N-(methyl-5'-trifluoromethyl phenyl)thiazol-2(3H)]ylidene)azine (13): Brownish oil; yield: 55%. IR (KBr) ν/cm⁻¹: 3494, 2922, 1721, 1622, 1544, 1508, 1320, 1251, 1173, 1120, 1015; 1H NMR (600 MHz, CDCl₃) δ: 7.74 (1H, d, J=4.8, C6-H), 7.25 (2H, d, J=8.4, 3',5'-PhH); 6.94 (2H, d, J=8.4, 2',6'-PhH); 5.84 (1H, s, 4-ArH); 4.83 (1H, s, -OH), 3.98 (1H, br, s, -OH), 3.71 (1H, br, s, C3-H), 3.73 (1H, br, s, -OH), 3.26 (3H, s, C3-H), 2.26 (1H, dd, J=9.0, 4.8, C7-H), 2.05 (2H, m, C8-H and C4-H); 0.96 (3H, s, C19-CH₃), 0.91 (3H, d, J=6.0, 21-CH₃); 0.85 (3H, d, J=6.6, 26- or 27-CH₃); 0.84 (3H, d, J=6.6, 26- or 27-CH₃); 0.66 (3H, s, C18-CH₃); 13C NMR (150 MHz, CDCl₃) δ: 171.3 (2-ArC), 161.7 (5-C), 158.9 (1'-PhC), 158.1 (1'-PhC), 151.2 (4-ArC), 131.6 (2'-PhC), 124.6 (4'-PhC), 115.6 (3',5'-PhH), 99.4 (4-ArC), 84.6 (5-C), 68.6 (3-C), 58.1 (17-C), 57.1 (14-C), 56.8 (7-C), 55.8 (9-C), 51.2 (13-C), 46.5 (10-C), 46.4 (12-C), 46.2 (24-C), 46.0 (N-CH₃), 41.3 (4-C), 40.9 (8-C), 37.6 (22-C), 37.1 (20-C), 30.0 (1-C), 29.7 (2-C), 29.4 (16-C), 28.5 (25-C), 26.3 (15-C), 25.2 (23-C), 24.2 (26-C), 24.0 (27-C), 23.0 (11-C), 20.3 (21-C), 20.2 (19-C), 14.0 (18-C); HREIMS m/z: 674.3968 [M+H]+ (calcd. for C_{38}H_{33}N_5F_3O_7S, 674.3967).

Citation: Huang Y, Qi B, Cui J, Liu Z, Gan C, et al. (2015) Synthesis and In Vitro Antiproliferative Evaluation of Some B-norcholesteryl thiazole Derivatives. Med chem 5: 405-411. doi: 10.4172/2161-0444.1000292
Compounds 19-24 were prepared similarly according to the procedure of 5-10, but using compound 18 as a reactive substrate. Compound 18 was prepared according to Gan et al. [20].

a1-(3β,5β-Dihydroxy-6'-B-norcholesteryl-6E-ylidene)-2-(3',5'-(p-chlorophenyl)thiazol-2(3H)-ylidene)azine (19): Yellow oil, yield: 62%. IR (KBr) v/cm−1: 3439, 2933, 2855, 1624, 1569, 1544, 1492, 1455, 1295, 1165, 1123, 1011; 1H NMR (600 MHz, CDCl3) δ: 7.63 (1H, d, J=5.4, C6-H), 7.28-7.04 (10H, m, Ph-H) 6.08 (1H, s, 4-ArH), 4.75 (1H, s, -OH), 3.96 (1H, s, C3-H), 3.84 (1H, br, s, -OH), 2.22 (1H, dd, J=9.6, 6.0, C7-H), 2.05-2.02 (2H, m, C8-H and C4-H), 0.95 (3H, s, 18-CH3), 0.91 (3H, d, J=6.6, 21-CH3), 0.87 (3H, d, J=6.6, 26- or 27-CH3), 0.86 (3H, s, 18-CH3); 13C NMR (150 MHz, CDCl3) δ: 171.0 (2-ArC), 160.4 (6-C), 141.7 (5-ArC), 138.8 (1-'NPhC), 132.5 (1'-PhC), 130.3 (1'-PhC), 129.0 (Ph-C), 129.8 (Ph-C), 129.7 (Ph-C), 129.1 (Ph-C), 102.0 (4-ArC), 84.7 (5-C), 85.3 (13-C), 57.1 (14-C), 57.0 (15-C), 46.6 (13-C), 46.2 (10-C), 45.8 (23-C), 44.5 (21-C), 43.0 (4-C), 41.9 (6-C), 37.7 (23-C), 35.0 (21-C), 34.8 (29-C), 32.6 (24-C), 28.3 (25-C), 26.8 (26-C), 25.3 (22-C), 24.6 (27-C), 23.0 (11-C), 20.3 (21-C), 20.2 (19-C), 14.0 (18-C); HREIMS m/z: 641.6055 [M+H]+ (calcd. for C39H33N2O3S, 651.4046).

b1-(3β,5β-Dihydroxy-6'-B-norcholesteryl-6E-ylidene)-2-(3',5'-(p-methoxyphenyl)thiazol-2(3H)-ylidene)azine (20): Yellow oil, yield: 63%. IR (KBr) v/cm−1: 3421, 2943, 2856, 1622, 1544, 1542, 1495, 1326, 1167, 1088; 1H NMR (600 MHz, CDCl3) δ: 7.63 (1H, d, J=5.4, C6-H) 7.42 (2H, d, J=8.4, 3.5'-PhH) 7.31 (2H, d, J=8.4, 2.6'-PhH) 7.26 (1H, t, J=7.2, N-PhH) 7.27-7.17 (4H, m, N-PhH) 6.20 (1H, s, 4-ArH) 4.65 (1H, br, s, -OH) 3.98 (1H, br, s, C3-H) 2.23 (1H, dd, J=9.6, 5.4, C7-H) 2.05-2.02 (2H, m, C8-H and C4-H), 0.94 (3H, s, 18-CH3), 0.88 (1H, d, J=6.6, 26- or 27-CH3), 0.60 (3H, s, 18-CH3); 13C NMR (150 MHz, CDCl3) δ: 170.6 (2-ArC), 160.1 (6-C), 140.4 (5-ArC), 138.5 (1'-NPhC), 136.0 (1'-PhC), 131.7 (1'-'C), 130.5 (3',5'-NPhC), 129.8 (2',6'-PhC), 129.7 (2',5'-NPhC), 126.7 (3',5'-PhC), 104.0 (4-ArC), 84.7 (5-C), 86.3 (3-C), 58.1 (17-C), 57.5 (14-C), 54.2 (5-C), 50.0 (9-C), 45.2 (13-C), 44.9 (10-C), 44.8 (12-C), 44.6 (24-C), 39.9 (N-PhC), 39.5 (3-C), 36.2 (8-C), 35.7 (22-C), 33.3 (20-C), 28.5 (21-C), 28.3 (26-C), 17.6 (22-C), 27.2 (14-C), 24.9 (25-C), 23.7 (15-C), 23.8 (23-C), 22.8 (26-C), 22.5 (27-C), 21.6 (11-C), 18.8 (18-C), 18.9 (19-C), 12.6 (18-C); HREIMS m/z 636.4200 [M+H]+ (calcd. for C39H33N2O3S, 636.4200).

c1-(3β,5β-Dihydroxy-6'-B-norcholesteryl-6E-ylidene)-2-(3'-nitrophenyl)thiazol-2(3H)-ylidene)azine (21): Brown oil, yield: 60%. IR (KBr) v/cm−1: 3451, 2933, 2855, 1629, 1591, 1546, 1491, 1420, 1198, 1197, 1105, 1078; 1H NMR (600 MHz, CDCl3) δ: 8.02 (2H, d, J=9.0, 3.5'-PhH), 7.63 (1H, d, J=5.4, C6-H), 7.32 (2H, t, J=7.2, N-PhH) 7.27 (1H, d, J=7.2, N-PhH) 7.22 (2H, d, J=9.0, 2.6'-PhH) 7.19 (2H, d, J=7.2, N-PhH) 6.31 (1H, s, 4-ArH), 4.52 (1H, s, -OH), 3.98 (1H, s, C3-H), 2.33 (2H, dd, J=9.6, 6.0, C7-H) 2.04-2.02 (2H, m, C8-H and C4-H), 0.93 (3H, s, 18-CH3), 0.90 (3H, d, J=6.6, 21-CH3), 0.85 (3H, d, J=6.6, 26- or 27-CH3), 0.84 (3H, s, 18-CH3); 13C NMR (150 MHz, CDCl3) δ: 170.2 (2-ArC), 161.4 (6-C), 148.5 (4'-PhC), 139.5 (5-ArC), 138.6 (1'-PhC), 138.5 (1'-NPhC), 130.7 (3',5'-NPhC), 130.2 (4'-NPhC), 130.0 (2',6'-NPhC), 129.6 (2',6'-NPhC), 125.0 (3',5'-PhC), 105.8 (4-ArC), 84.7 (5-C), 86.8 (3-C), 58.1 (17-C), 57.1 (14-C), 55.8 (7-C), 51.3 (9-C), 46.6 (13-C), 45.2 (24-C), 43.1 (4-C), 40.9 (8-C), 37.6 (22-C), 37.1 (20-C), 29.9 (18-C).
d) 1-(3β,5β-Dihydroxy-6'-B-norcholesteryl-6E-ylidene)-2-[N-phenyl-5'-p-chlorophenyl] thiazol-2(3H)-ylidene](azine (22): Yellow oil, yield: 80%. IR(KBr)\(\text{cm}^{-1}\): 3444, 2943, 2858, 1622, 1582, 1544, 1448, 1447, 1397, 1355, 1298, 1165, 1011; 1'H NMR (600 MHz, CDCl\(_3\)), \(\delta\): 7.61 (1H, d, \(J=5.4, C6-H\)), 7.29 (2H, J = 7.2, 3',5'-NPhH), 7.24 (1H, J = 7.2, 2',6'-NPhH), 7.16 (2H, J = 7.2, 2',6'-NPhH), 7.13 (2H, J = 8.4, 3',5'-PhH), 6.98 (2H, J = 8.4, 2',6'-PhH), 6.09 (1H, s, 4-ArH), 4.67 (1H, s, -OH), 3.96 (1H, s, C3-H), 2.21 (1H, dd, J= 9.5, 5.4, C7-H), 2.04-2.01 (2H, m, C8-H and C4-H), 0.93 (3H, s, 19-CH\(_3\))

\(\text{C} 20.2 (19-C), 14.0 (18-C); \text{HREIMS } m/z: 693.4203 [M+H]\) (calcd. for C\(_{43}\)H\(_{29}\)N\(_2\)O\(_3\), 693.4202).

\text{Biological assays}

\text{Materials:} Stock solutions of the compounds were prepared in sterile dimethyl sulfoxide (DMSO) (Sigma) at a concentration of 10 mg/mL and afterward diluted with complete nutrient medium (RPMI-1640) supplemented with 10% heat inactivated fetal bovine serum and 0.1% gelatin. Cells were seeded in the medium (RPMI-1640) supplemented with 10% heat inactivated fetal bovine serum and 0.1% gelatin. Cells were incubated for 4 h. After the supernatant was discarded, 200 µL of DMSO was added to dissolve the yellow formazan crystals formed. The absorbance values (A) at 492 nm were determined using a MLLITTSKAN MK3 analysis spectrometer. The IC\(_{50}\) values were calculated as the concentration of drug yielding 50% cell survival.

Conclusions

We synthesized some novel B-norcholesteryl thiazole derivatives. Their structures were characterized by IR, NMR and HREIMS. The antiproliferative activity of the compounds against human cervical carcinoma (HeLa), human lung carcinoma (A549), human liver carcinoma cells (HEPG2) and normal kidney epithelial cells (HEK293T) was assayed. The results showed that some compounds with the structure of N-methylthiazole displayed distinct antiproliferative activity against A549 and HEPG2 cells. In addition, compounds with the structure of N-phenylthiazole exhibited a selective antiproliferative activity on HeLa cells and were almost inactive to normal kidney epithelial cells (HEK293T). The research provided a theoretical reference for the exploration of new anti-cancer agents and may be useful for the design of novel chemotherapeutic drugs.

Acknowledgments

The authors acknowledge the financial support of the National Natural Science Foundation of China (No: 21462009) and the Guangxi Colleges and University Key Laboratory Foundation of Beibu Gulf Oil and Natural Gas Reseource Effective Utilization.

References

1. Troisi L, Florio S, Granito C (2002) Chemoselective construction of novel steroid derivatives. Steroids 67: 687-693.
2. Mohareb RM, Elmegeed GA, Abdel-Salim OM, Doss SH, William MG (2011) Synthesis of modified steroids as a novel class of non-ulcerogenic, anti-inflammatory and anti-nociceptive agents. Steroids 76: 1190-1203.
3. KRSTIĆ NM, Bjelaković MG, Pavlović VD, Robeyns K, Juranić ZD, et al. (2012) New androst-4-en-17-spiro-,3,2-oxathiaphospholanes. Synthesis, assignment of absolute configuration and in vitro cytotoxic and antimicrobial activities. Steroids 77: 585-665.
4. Mohareb RM, Al-Omran F (2012) Reaction of pregnenolone with cyanoacetylhydrazine: novel synthesis of hydrazide-hydrazone, pyrazole, pyridine, thiazole, thiophene derivatives and their cytotoxicity evaluations. Steroids 77: 1581-1599.
5. Festi D, Montagnani M, Azzaroli F, Lodato F, Mazzella G, et al. (2007) Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. Curr Clin Pharmacol 2: 155-177.

6. Chen SJ, Cui JG, Li Y, Fan LH (2011) Recent Advance of Steroidal Hydrazones with Biological Activities. Chinese J Org Chem 31: 187-192.

7. Zhang XJ, Cui JG, Li Y, Chen SJ (2010) Recent advance in steroidal oximes with biological activity. Chinese J Org Chem 30: 655-661.

8. Trafaslis DT (2006) Hybrid aza-steroid alkylators in the treatment of colon cancer. Cancer Lett 243: 202-210.

9. Blunt JW, Copp BR, Keyzers RA, Munro MH, Prinsep MR (2013) Marine natural products. Nat Prod Rep 30: 237-323.

10. Blunt JW, Copp BR, Keyzers RA, Munro MH, Prinsep MR (2014) Marine natural products. Nat Prod Rep 31: 160-258.

11. Blunt JW, Copp BR, Keyzers RA, Munro MH, Prinsep MR (2015) Marine natural products. Nat Prod Rep 32: 116-211.

12. Salvador JA, Carvalho JF, Neves MA, Silvestre SM, Leltao AJ, et al. (2013) Anticancer steroids: linking natural and semi-synthetic compounds. Nat Prod Rep 30: 324-374.

13. Wentworth P Jr, Nieva J, Takeuchi C, Galve R, Wentworth AD, et al. (2003) Evidence for ozone formation in human atherosclerotic arteries. Science 302: 1053-1056.

14. Wang HL, Fang JM, Cheng YS (1998) Diterpenoids and steroids from Taiwania cryptomerioides. Phytochemistry 48: 1391-1397.

15. Miyamoto T, Kodama K, Agramaki Y, Higuchi R, Soest RWM (2001) Orostanal, a novel abeo-sterol inducing apoptosis in leukemia cell from a marine sponge, Stelletta hiwasaensis. Tetrahedron Lett 42: 6349-6351.

16. Xiaomei W, Abinael DR, Yuehong W, Scott GF (2007) Novel ring B abeo-sterols as growth inhibitors of mycobacterium tuberculosis isolated from a Caribbean Sea sponge, Svenzea zeal. Tetrahedron Lett 48: 8851-8854.

17. Xiaomei W, Abinael DR, Yuehong W, Scott GF (2008) Synthesis and in vitro biological evaluation of ring B abeo-sterols as novel inhibitors of Mycobacterium tuberculosis. Bioorganic & Medicinal Chemistry Letters 18: 5448-5450.

18. Gan C, Fan L, Cui J, Huang Y, Jiao Y, et al. (2012) Synthesis and in vitro antiproliferative evaluation of some ring B abeo-sterols. Steroids 77: 1061-1068.

19. Gan C, Fan L, Huang Y, Liu Z, Cui J (2013) Synthesis of novel ring B Abole-sterol derivatives and their antiproliferative activities. Med Chem 9: 846-854.

20. Gan C, Lin Q, Cui J, Feng J, Guo J, et al. (2014) Synthesis and in vitro antiproliferative evaluation of some novel B-norcholesterols. Steroids 79: 37-43.

21. Singh H, Kapoor VK, Paul D (1979) Heterosteroids and drug research. In: Progress in Medicinal Chemistry, Ellis GP, West GB. Eds.; Springer: Amsterdam, 16: 35-150.

22. Singh H, Jindal DP, Yadav MR, Kumar M (1991) Heterosteroids and drug research. In Progress in Medicinal Chemistry, Ellis GP, West GB. Eds.; Elsevier science publishers: Amsterdam, 28: 233-300.

23. Cui JG, Liu L, Gan CF, Xiao Q, Huang YM (2014) Recent progress in synthesis and biological activity of steroids bearing aromatic rings and heterocycles. Progress in Chem 26: 320-333. (in Chinese).

24. Ma B, Xiao ZY, Chen YJ, Lei M, Meng YH, et al. (2013) Synthesis and structure-activity relationships study of cytotoxic bufalin 3-nitrogen-containing-ester derivatives. Steroids 78: 508-512.

25. Guo H, Zhang G, Zhang T, He X, Wu Z, et al. (2011) Synthesis, characterization and biological evaluation of some 16β-azolyl-3β-amino-5α-androstane derivatives as potential anticancer agents. Eur J Med Chem 46: 3662-3674.

26. Huang LH, Zheng YF, Lu YZ, Song CJ, Wang YG, et al. (2012) Synthesis and biological evaluation of novel steroid[17,16-D][2,4]triazolo[5-a]pyrimidinones. Steroids 77: 710-715.

27. Kovacs D, Motyan G, Wolling J, Kovacs I, Zupko I, et al. (2014) A facile access to novel steroidal 17-Z-(1′,3′,4′)-oxadiazolones, and an evaluation of their cytotoxic activities in vitro. Bioorg Med Chem Lett 24: 1265-1268.

28. Zhang BL, Zhang E, Pang LP, Song LX, Li YF, et al. (2013) Design and synthesis of novel D-ring fused steroidal heterocycles. Steroids 78: 1200-1208.

29. Cui J, Qi B, Gan C, Liu L, et al. (2015) Synthesis and in vitro antiproliferative evaluation of some B-norcholesteryl Benzimidazole and Benzothiazole derivatives, Mar Drugs 13: 2488-2504.

30. Lesyk R, Zimenkovskiy B, Atamanyuk D, Jensen F, Kononowicz KK, Gazella A (2006) Anticancer thiopyran[2,3-d][1,3]thiazol-2-ones with norbornean moiety. Synthesis, cytotoxicity, physico- chemical properties, and computational studies. Bioorg Med Chem 14: 5230-5240.

31. Kashti K (2009) Anti-inflammatory agents as cancer therapeutics. Adv Pharmacol 57: 31-89.

32. Ramla MM, Omar MA, El-Khamary AM, El-Diwani HI (2006) Synthesis and antitumor activity of 1-substituted-2-methyl-5-nitrobenzimidazoles. Bioorg Med Chem 14: 7324-7332.

33. Sun LP, Jiang Z, Gao LX, Liu XF, Quan YC, et al. (2013) Synthesis and PTP1B inhibitory activity of (E)-1-substitutedphenyl-3-(4-(E)-(2-(4-phenylthiazol-2-yl) hydrazono)-methyl)phenoxy)-prop-2-en-1-ones. Chin J Org Chem 33: 1496-1502.

34. Liu B, Zhou WS (2003) The first stereoselective synthesis of orostanal isolated from a marine sponge Stelletta hiwasaensis. Tetrahedron 59: 3379-3384.

35. Natalie KC, Johanna CS, Terry DB, Wentworth JrP (2011) Addition of cholesterol 5,6-secosterol aldehyde to membrane-bound myelin basic protein exposes an immunodominant epitope. Biochemistry 50: 2092-2100.